Corrigendum to "design, Synthesis, and Biological Evaluation of 1,6-Naphthyridine-2-one Derivatives As Novel FGFR4 Inhibitors for the Treatment of Colorectal Cancer" [eur. J. Med. Chem. 259 (2023) 115703/5].